Nuformix plc (LON:NFX – Get Free Report) shot up 9.2% on Thursday . The stock traded as high as GBX 0.20 and last traded at GBX 0.20. 4,340,332 shares changed hands during mid-day trading, a decline of 88% from the average session volume of 37,526,156 shares. The stock had previously closed at GBX 0.19.
Nuformix Stock Performance
The firm has a fifty day simple moving average of GBX 0.18 and a 200 day simple moving average of GBX 0.22. The stock has a market cap of £5.27 million, a price-to-earnings ratio of -6.89 and a beta of 1.55.
Nuformix (LON:NFX – Get Free Report) last released its quarterly earnings data on Thursday, May 28th. The company reported GBX (0.02) earnings per share (EPS) for the quarter.
About Nuformix
Nuformix plc operates in the field of pharmaceutical development for treating fibrosis and oncology through drug repurposing in the United Kingdom. It offers NXP001, which has completed Phase 1 for use in oncology supportive care. The company is also developing NXP004, a novel form of Olaparib, which is in the IP generation phase for treating oncology; and NXP002 that is in pre-clinical stage for the treatment of idiopathic pulmonary fibrosis. It also has an option agreement with Oxilio Ltd. for NXP001 for oncology indications.
Featured Stories
- Five stocks we like better than Nuformix
- Time to Sell? 3 Winners With Fading Technical Momentum
- Why These 2 Hotel Stocks Are Beating Travel Peers
- This Energy Stock Has Quietly Soared 130% in a Year
- 3 ‘Boring’ Dividend Stocks With Tasty Technical Setups
Receive News & Ratings for Nuformix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nuformix and related companies with MarketBeat.com's FREE daily email newsletter.
